COGNITIVE IMPAIRMENT TREATMENT IN ARTERIAL HYPERTENSION WITH DIABETES MELLITUS 2ND TYPE

Aim. To develop the method and media for cognitive impairment correction in patients with arterial hypertension, combined with diabetes mellitus 2nd type.

Material and methods. Totally 120 included with essential arterial hypertension (EAH), associated with diabetes 2nd type, with insufficient blood pressure (BP) level control. Patients with AH had 2nd grade of BP increase with mild of moderate compensated DM 2nd type with the level of glycosylated hemoglobin about 6,25%. The patients had quite high number of concomitant diseases and risk factors. All patients received basic antihypertensive therapy (beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor inhibitors). Also the patients took the drugs for concomitant pathology (hypolipidemic drugs, nitrates, glucose lowering drugs). The necessary criteria for inclusion was informed consent. At outpatient stage of the study, first visit and in a year the complex of events was done: anamnesis and complaints clarification; palpation and auscultation of the heart and major vessels; BP measurement on upper extremities by Korotkov; ECG registration, Echocardiography. The biochemical sampling of fasting plasma was done: the level of glucose was measured, of glycosylated hemoglobin, lipid profile (cholesterol, triglycerides, LDL, HDL), clotting parameters (INR, APTT, fibrinogen), electrolytes (K, Mg). Also the patients completed medical questionnaires of a specific purpose. The score of psychic status was used: MINI-MENTAL STATE EXAMINATION (MMSE) M.F. FOLSTEIN, S.E. FOLSTEIN, P.R. HUGH, 1975. And if there were prominent cognitive disorders Kudesan® was prescribed — mitochondrial coenzyme Q10 — at the dosage of 60 mg per day during the next 2 months. Dosage of the drug used according to medical instructions.

Results. The data witnesses that clinical effect was achieved in patients with Kudesan®: the significant improvement of cognitive functions in patients by MMSE score. The effectiveness of Q10 compound was measured by the clinical properties matching after the treatment. Before the treatment the clinical data compared were identical with the absence of statistical significance among them (p>0,01).

Conclusion. The positive influence of complex therapy is shown on the cognitive functions in patients with AH at the background of diabetes 2 type. The study showed that the inclusion of Q10 compound into the standard treatment of arterial hypertension with diabetes 2nd type is associated with positive clinical effect, especially in relevant cognitive function improvement, significant decrease of systolic and diastolic BP, relevant decrease of blood pressure variability, significant of glucose and glycosylated hemoglobin level decrease, significant Mg level increase.

1. Goldstein LB, Adams R. P rimary prevention of ischemic stroke. Circulation 2006; 63: 873-923.

2. Messerli F. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008; 52: 1482-9.

3. Shalnova SA. Arterial hypertension and commitment therapy. Vrach. 2009; 12: 39-42. Russian (Шальнова С. А. Артериальная гипертензия и приверженность терапии. Врач. 2009; 12: 39-42).

4. Kobalava JD, Kotovskaya YV, Villevalde SV, et al. The Possibilities for improving the control of hypertension by rational use of diuretics on the results of the Russian scientificpractical program ARGUS-2. Cardiovascular Therapy and Prevention 2007; 6(3): 61-7. Russian (Кобалава Ж. Д., Котовская Ю. В., Виллевальде С. В.и др. Возможности улучшения контроля артериальной гипертонии путем рационального использования диуретиков по результатам Российской научно-практической программы АРГУС-2. Кардиоваскулярная терапия и профилактика 2007; 6(3): 61-7).

5. Tsuboyama-Kasaoka N, Shozawa C, Sano K, et al. Taurine (2-Aminoethanesulfonic Acid) deficiency creates a vicious circle promoting obesity. Endocrinology 2006; 147: 3276-84.

6. Manschot SM, Brands AM, van der Grond J, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006; 55: 1106-13.

7. Jefferson A, Benjamin E . C ardiovascular disease, cognitive decline and dementia. Vascular cognitive impairment in clinical practice. Eds. L. Wahlung TErkinjuntti, S. Gauthier. Cambridge 2009: 166-77.

8. Vogels R, Oosterman J, Harten B . Neuroimaging and correlates of cognitive function among patients with heart fatiure. Dement Geriatr Cogn Disord 20074 24: 418-23.

9. Yakhno NN. Cognitive disorders in the neurological clinic Nebr. Journ 2006; 11: 4-12. Russian (Яхно Н. Н. Когнитивные расстройства в неврологической клинике Невр. журн. 2006; 11: 4-12).

10. Van den Berg E, Kessels RP, Kappelle LJ, et. al. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. Drugs Today (Barc). 2006; 42(11): 741-54.

11. Levin OS, Golubeva LV. Heterogeneity moderate cognitive disorders: diagnostic and therapeutic aspects. Consilium Medicum 2006; 12: 106-10. Russian (Левин О. С., Голубева ЛВ. Гетерогенность умеренного когнитивного расстройства: диагностические и терапевтические аспекты. Consilium Medicum 2006; 12: 106-10).

12. Method and means of correction of cognitive impairment in patients with arterial hypertension associated with diabetes mellitus type 2. Priority help from 29 June 2014 No. 2014131439. The owner of the SSMU together with the authors: Tyukalova LI, Lukyanova MA. Russian (Способ и средства коррекции когнитивных нарушений у пациентов с артериальной гипертонией ассоциированной с сахарным диабетом 2 типа. Приоритетная справка от 29 июня 2014 г. № 2014131439. Обладатель СибГМУ совместно с авторами: Тюкалова Л. И., Лукьянова М. А.).

13. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic hypertension 2010; 3: р. 34. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3; с 34).

14. Belova AN. Scales and questionnaires in neurology and neurosurgery. M., 2004. p. 432. Russian (Белова А. Н. Шкалы и опросники в неврологии и нейрохирургии. М., 2004. c. 432).